Revvity Inc vs Zscaler Inc — how do they compare? Revvity Inc trades at $154.1 (market cap $16.98B), while Zscaler Inc trades at $233.96 (market cap $35.35B). The key difference: Zscaler Inc is far larger — about 2.1× Revvity Inc's market cap, and Revvity Inc pays a 0.18% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Zscaler Inc for 41 Days on average.
| RVTY | ZS | |
|---|---|---|
Market Cap | $16.98B | $35.35B |
Volume | 1,456,900 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $157.36 | $336.27 |
52-Week Low | $82.26 | $118.05 |
Typical Hold Time | 12 Days | 41 Days |
Enterprise Value | $19.30B | $33.73B |
Dividend Yield | 0.18% | — |
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Zscaler (ZS) trades at $233.73, up 9.45% today, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. Revenue growth is robust, rising from $1.1B in 2022 to $2.67B in 2025, though the company remains unprofitable with a net margin of -1.88%. Recent news includes a CRO transition and an upcoming Investor Day, while analyst sentiment is overwhelmingly positive with 79.6% buy ratings.
The stock offers growth potential driven by cybersecurity demand and AI product adoption, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target of $222.83 suggests modest downside from current levels, requiring careful risk assessment amid volatile market conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →